A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC 820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Advanced breast cancer; Brain metastases; Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- 01 Aug 2024 Planned End Date changed from 1 Dec 2026 to 1 Dec 2028.
- 01 Aug 2024 Planned primary completion date changed from 17 Feb 2025 to 31 Dec 2027.
- 21 Nov 2022 Planned End Date changed from 1 Feb 2025 to 1 Dec 2026.